Cancer cells induce interleukin-22 production from memory CD4<sup>+</sup>T cells via interleukin-1 to promote tumor growth

Cornelia Voigt(Center for Integrated Protein Science Munich), Peter May(Center for Integrated Protein Science Munich), Adrian Gottschlich(Center for Integrated Protein Science Munich), Anamarija Markota(Center for Integrated Protein Science Munich), Daniel Wenk(Center for Integrated Protein Science Munich), Inga Gerlach(Center for Integrated Protein Science Munich), Sebastian Voigt, Georgios T. Stathopoulos(University of Patras), Kristina A. M. Arendt(Helmholtz Zentrum München), Constanze Heise(Center for Integrated Protein Science Munich), Felicitas Rataj(Center for Integrated Protein Science Munich), Klaus‐Peter Janssen(TUM Klinikum), Mélanie Königshoff(Helmholtz Zentrum München), H. Winter(German Center for Lung Research), Isabelle Himsl, Wolfgang E. Thasler(Ludwig-Maximilians-Universität München), Max Schnurr(Center for Integrated Protein Science Munich), Simon Rothenfußer(Center for Integrated Protein Science Munich), Stefan Endres(Center for Integrated Protein Science Munich), Sebastian Kobold(Center for Integrated Protein Science Munich)
Proceedings of the National Academy of Sciences
November 17, 2017
Cited by 134Open Access
Full Text

Abstract

Significance IL-22 has been identified as a cancer-promoting cytokine, but its regulation in cancer tissue has not been addressed. Using both murine and human models, we demonstrate that cancer cells directly induce IL-22 production. We prove that interleukin-1β induced by inflammasome activation is critical for IL-22 production. IL-1β increased the activity of the IL-22 transcription factors in lineage-committed T cells. We show the existence of IL-22–producing Th1, Th17, and Th22 cells in tumor tissue of patients. Use of the clinically approved IL-1 receptor antagonist anakinra in vivo reduced IL-22 production and reduced tumor growth in a breast cancer model. These data provide the basis for therapeutic interventions, particularly using anakinra, aiming at limiting IL-22 production in patients with cancer.


Related Papers

No related papers found

Powered by citation graph analysis